Roche Türkiye

What Roche Türkiye does

Roche Türkiye is the Turkish affiliate of the global Roche Group (F. Hoffmann-La Roche Ltd, publicly traded on the SIX Swiss Exchange), operating through two Istanbul-based corporate entities: Roche Müstahzarları Sanayi A.Ş. for pharmaceuticals and Roche Diagnostics Turkey A.Ş. for in vitro diagnostics. Founded in Turkey in 1958 and employing approximately 190 people, the company sells innovative medicines across six therapeutic areas — respiratory diseases, hematology, neurology, oncology, rheumatology, and ophthalmology — and a comprehensive diagnostics portfolio spanning women's health, cardiology, infectious diseases, pathology, oncology, and diabetes management through the Accu-Chek brand.

The technology stack combines therapeutic biologics and small molecules with in vitro diagnostic systems, including high-sensitivity cardiac troponin T and NT-proBNP biomarkers, HPV testing, automated digital pathology scoring, and tissue staining workflows. The parent group's Institute of Human Biology in Basel develops 2D/3D human tissue and organ miniatures from stem cells for drug discovery, supporting personalized healthcare positioning. The diagnostics side supplies instruments and reagents directly to clinical laboratories, while pharmaceuticals flow through pharmacy networks and direct hospital sales across Turkey.

Revenue is generated through one-time pharmaceutical sales, hardware and consumable sales in diagnostics, and professional services including medical education and clinical support. Pricing is negotiated privately with healthcare institutions and insurers and is not publicly disclosed. Go-to-market relies on enterprise field sales targeting specialists (oncologists, cardiologists, neurologists), complemented by medical congress participation, university clinical research collaborations (notably with İnönü University), and physician engagement platforms such as Medikaynak. Customer segments are hospitals, clinics, physicians, clinical laboratories, and ultimately patients across Turkey, served under ISO 9001, ISO 27001, GDPR, and Turkey's KVKK compliance frameworks.

Name

Roche Türkiye

Legal name

Roche Müstahzarları Sanayi Anonim Şirketi ve Roche Diagnostics Turkey Anonim Şirketi

Website

https://roche.com.tr

Company type

Private

Founded year

1896

Operating status

Operating

Headcount range

101–250 employees

Short description

Roche Türkiye is the Turkish affiliate of Roche Group, selling innovative pharmaceuticals across six therapeutic areas and in vitro diagnostics (including the Accu-Chek diabetes brand) to hospitals, clinics, physicians, and clinical laboratories across Turkey via direct sales, pharmacy distribution, and laboratory supply channels.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Oncology Specialty Pharmaceuticals (HLAIACAA)

akta.pro secondary industries

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

Keywords

• Pharmaceutical products
• In vitro diagnostics
• Oncology therapeutics
• Diagnostic solutions
• Prescription medicines

Headquarters

HQ city

İstanbul

HQ country

Türkiye

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Pharmaceutical Products: Sale of innovative medicines for treatment of chronic and life-threatening diseases including respiratory, hematology, neurology, oncology, rheumatology, and ophthalmology conditions.
2. Diagnostic Solutions: Sale and distribution of in vitro diagnostic products and solutions including tests for infectious diseases, cardiology, oncology, women's health, and diabetes management.
3. Professional Services: Medical education, training, and clinical support services provided to healthcare professionals and institutions.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Core offering

Roche Türkiye operates as the Turkish subsidiary of the global Roche Group, selling innovative pharmaceutical medicines across six therapeutic areas (respiratory, hematology, neurology, oncology, rheumatology, ophthalmology) and providing in vitro diagnostic solutions spanning women's health, cardiology, infectious diseases, pathology, oncology, and diabetes care through the Accu-Chek brand. The company distributes products directly to hospitals, clinics, physicians, and clinical laboratories across Turkey under two legal entities: Roche Müstahzarları Sanayi A.Ş. (pharmaceuticals) and Roche Diagnostics Turkey A.Ş. (diagnostics).

Product overview

Roche Türkiye operates two distinct entities: Roche Müstahzarları Sanayi A.Ş. (pharmaceuticals) and Roche Diagnostics Turkey A.Ş. (diagnostics). The pharmaceutical division offers treatment solutions across six therapeutic areas: Respiratory Diseases, Hematology, Neurology, Oncology, Rheumatology, and Ophthalmology. The diagnostics division provides in vitro diagnostic solutions covering Women's Health, Cardiology, Infectious Diseases, Pathology, and Oncology diagnostics, along with the Accu-Chek diabetes care brand. The company also conducts research through the Institute of Human Biology in Basel. Employee benefits include flexible work programs (RocheFlex/Roche Vitrin), education support, and language training.

Differentiator

Problem solved

Functional benefit

Brands

• Accu-Chek: Diabetes care brand offering blood glucose monitoring solutions and products for diabetes management.

Products and services

• Respiratory Diseases Treatment Solutions
• Hematology Treatment Solutions
• Neurology Treatment Solutions
• Oncology Treatment Solutions
• Rheumatology Treatment Solutions
• Ophthalmology Treatment Solutions
• Women's Health Diagnostics
• Cardiology Diagnostics
• Infectious Diseases Diagnostics
• Pathology Diagnostics
• Oncology Diagnostics
• Accu-Chek Diabetes Care

Quantifiable outcome

• Over 30 Roche drugs are listed in WHO Essential Medicines List
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

One partnership is on record.

• İnönü Üniversitesi (Inönü University)coreStrategic or Co-development Partner · 24 June 2025Roche Türkiye and İnönü University collaboration established the Clinical Research and Center of Excellence Application and Research Center Support Unit following the 2023 Kahramanmaraş earthquakes. The partnership aims to strengthen healthcare infrastructure and clinical research capabilities in Turkey.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Market position

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCdAVlrkubS7MQI_u4bxl4dw
• Facebookfacebook.com/RocheTurkey
• LinkedInlinkedin.com/company/roche-turkiye
• Instagraminstagram.com/rocheturkiye

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Roche Türkiye